Skip to Main Content
Contribute Try STAT+ Today

In a bid to calm anxious patients, the Food and Drug Administration has extended the shelf life of a drug used to treat a rare form of glaucoma, which Pfizer (PFE) recently discontinued and may disappear altogether unless the company finds a suitable buyer.

The agency sent a notice to health care providers on Wednesday indicating that the shelf life for the medicine, known as phospholine iodide, would now run 12 months beyond the date stamped on its packaging, which would make “additional limited inventory of product available.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment